Related content

Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics

By Mattison Lori K   Soong Richie   Diasio Robert B  

Pharmacogenomics, Vol. 3, Iss. 4, 2002-07 ,pp. : 485-492

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetics of Colon Cancer and Potential Implications for 5- Fluorouracil-Based Chemotherapy

By  

Current Pharmacogenomics, Vol. 4, Iss. 1, 2006-03 ,pp. : 57-67

Bentham Science Publishers

Access to resources Recommend Favorite

Dihydropyrimidine Dehydrogenase Genotyping and Phenotyping for 5- Fluorouracil Dysmetabolism: Moving Towards Personalized Chemotherapy in Patients with Cancer

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 7, Iss. 4, 2009-12 ,pp. : 275-283

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase

By  

Current Pharmaceutical Design, Vol. 23, Iss. 14, 2017-05 ,pp. : 2028-2034

Bentham Science Publishers

Access to resources Recommend Favorite

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

By Amstutz Ursula   Froehlich Tanja K   Largiadèr Carlo R  

Pharmacogenomics, Vol. 12, Iss. 9, 2011-09 ,pp. : 1321-1336

Future Medicine

Access to resources Recommend Favorite